ANF vs BABA

ANF has a stable Piotroski F-Score of 6/9, indicating moderate financial health, but lacks an Altman Z-Score, limiting definitive conclusions on bankruptcy risk. The stock trades above both the Graham Number ($81.46) and intrinsic value estimate ($71.89), suggesting overvaluation, despite strong profitability metrics like 40.89% ROE and 12.77% ROA. While revenue growth is positive at 6.80%, earnings are contracting YoY (-5.6%) and QoQ (-14.4%), and insider selling signals caution. Analysts recommend a 'buy' with a high target price of $127.56, but recent price performance shows significant short-term weakness (-24% in 1M).

The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.